The FDA has approved Danziten™, a nilotinib formulation with no mealtime restrictions, for the treatment of adults with newly diagnosed Ph+ CML-CP and resistant or intolerant Ph+ CML-CP and CML-AP.

Patients with chronic myeloid leukemia who have attained sustained deep molecular response with second-line nilotinib therapy can achieve treatment-free remission for 48 weeks or longer, according ...

In the non-hyperlipidemia group, patients receiving nilotinib were significantly more likely to develop CVD than those treated with imatinib (IRR, 3.21).

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that does not require mealtime restrictions, to ...

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten) for chronic myeloid leukemia (CML), making this version of the tyrosine kinase inhibitor (TKI) the only one ...

The Food and Drug Administration (FDA) approved Danziten, a formulation of nilotinib, that requires no mealtime restrictions for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

In a study of 43 DLB patients, nilotinib improved cognition scores by 2.8 points versus placebo (P=0.037) on the Alzheimer's Disease Assessment Scale-Cognitive Subscale 14 (ADAS-Cog14) at 3 months ...